| NEW YORK
NEW YORK Feb 28 Dow Chemical Co said it
remains unclear how much in interest and other costs will be
added to an expected $2.16 billion arbitration payment from a
Kuwaiti firm that scuttled a 2008 joint venture, information
that had been expected by Thursday.
In late 2008 Dow Chemical planned a $17.4 billion joint
venture with Petrochemical Industries Co (PIC) of Kuwait to spin
off its basics plastics business into a stand-alone company
PIC pulled out of the deal in December 2008, citing the
then-deteriorating global economy. An arbitrator ruled last year
that PIC was at fault and owed Dow Chemical $2.16 billion, plus
interest and costs.
The funds are crucial to Dow Chemical's plans to cull its
$20.99 billion debt load, more than half its market value.
Dow Chemical CEO Andrew Liveris told investors on a January
31 conference call that interest and costs were not included in
that award. "We are now simply awaiting the release of the final
award to the parties, which we expect to receive in February,"
On Thursday Dow clarified that the company did not expect to
receive a full payment by the end of the month, but rather
information about how much interest and other costs would be
added to the $2.16 billion award.
Dow Chemical has not received that information, nor the
final payout, spokeswoman Nancy Lamb said.
Information on the amount of the final award should come in
"the near future," Lamb said, noting the company hopes to get
nearly $2.5 billion.
Lamb declined to comment when asked when Midland,
Michigan-based Dow Chemical expected final payout.
"We have every reason to believe that PIC will honor its
contractual commitment," Lamb said.
PIC, a unit of the Kuwait Petroleum Corp, was not
immediately available to comment outside of business hours.
Dow Chemical and PIC currently operate three other joint
ventures, including ME Global, EQUATE and Kuwait Olefins Co.
The December 2008 cancellation of the K-Dow joint venture
had raised fears at the time among investors that Dow Chemical
would be unable to finance its planned $15 billion purchase of
specialty chemicals maker Rohm & Haas, a key plank in Liveris'
strategy to shift the company toward the higher margin business.
That deal only closed in mid-2009 after Dow and Rohm & Haas
altered the terms, avoiding a trial at the last minute that had
been filed by Rohm.
Shares of Dow Chemical fell 0.5 percent to $31.65 in